Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry
- 15 July 2013
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (7), 907-914
- https://doi.org/10.1111/jdv.12208
Abstract
Background There are few data on the prevalence of obesity in the general psoriasis population and on the real impact of obesity on the management of psoriasis patients in the clinical setting. Objectives To evaluate the prevalence of overweight and obesity in patients with moderate‐to‐severe psoriasis compared to the general population and to assess the relationship between Body Mass Index (BMI) and the risk of discontinuing treatment. Methods Patients registered on Biobadaderm, a prospective registry, were grouped according the different categories of BMI and compared to the general Spanish population. Drug survival was analysed considering only drug withdrawal due to lack of effectiveness, remission and adverse events. Results A total of 1162 moderate‐to‐severe psoriasis patients on systemic conventional or biological treatment were recruited. The prevalence of obesity was found to be significantly higher in psoriasis patients than in the general Spanish population (P < 0.001). In multivariate analysis a 5‐unit increase in BMI, similar to a change in BMI category from normal weight to overweight and from overweight to obesity, was associated with a 12% increased risk of discontinuing therapy due to lack of effectiveness (HR 1.12, 95% CI: 1.01–1.24) and with a 17% increased risk of having an adverse event (HR 1.17, 95% CI: 1.02–1.36), both independently of the drug used. Conclusions Patients with moderate‐to‐severe psoriasis had a higher prevalence of obesity than the general population. Increased BMI was associated with an increased risk of treatment discontinuation due to lack of effectiveness and a higher risk of adverse events.Keywords
Funding Information
- Spanish Medicines and Health Products Agency (AEMPS)
- Abbott
- Pfizer
- MSD
- Janssen
This publication has 22 references indexed in Scilit:
- Cost‐efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate‐to‐severe plaque psoriasisJournal of the European Academy of Dermatology and Venereology, 2011
- BIOBADADERM: registro español de acontecimientos adversos de terapias biológicas en Dermatología. Primer informeActas Dermo-Sifiliograficas, 2011
- Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and reviewBritish Journal of Dermatology, 2007
- Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in WomenArchives of Internal Medicine, 2007
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- The endocrine function of adipose tissue: an updateClinical Endocrinology, 2006
- Cigarette Smoking, Body Mass Index, and Stressful Life Events as Risk Factors for Psoriasis: Results from an Italian Case–Control StudyJournal of Investigative Dermatology, 2005
- Tablas de evaluación del riesgo coronario adaptadas a la población española. Estudio DORICAMedicina Clinica, 2004
- Prevalence of psoriasis in Spain (Epiderma Project: phase I)Journal of the European Academy of Dermatology and Venereology, 2001
- Diseases Associated with Psoriasis in a General Population of 159,200 Middle-Aged, Urban, Native SwedesDermatology, 1986